CT-guided navigated microwave ablation (MWA) of an unfavorable located breast cancer metastasis in liver segment I. by Fischer, Tim Steffen et al.
R a d i o l o g y  Ca s e  R e p o r t s  1 4  ( 2 0 1 9 )  1 4 6 – 1 5 0  
Available online at www.sciencedirect.com 
journal homepage: www.elsevier.com/locate/radcr 
Case Report 
CT-guided navigated microwave ablation (MWA) of 
an unfavorable located breast cancer metastasis in 
liver segment I 
Tim Fischer, MD, Dr. med.a , Anja Lachenmayer, MD, Priv.-Doz. Dr. med.b , 
Martin Helmut Maurer, MD, MBA, Priv.-Doz. Dr. med. Dr. rer. medic c , ∗
a Department of Diagnostic, Interventional and Paediatric Radiology, Bern University Hospital, Inselspital, University 
of Bern, Freiburgstr. 10, 3010 Bern, Switzerland 
b Department of Surgery, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 10, 3010 Bern, 
Switzerland 
c Department of Diagnostic, Interventional and Paediatric Radiology, Bern University Hospital, Inselspital, University 
of Bern, Freiburgstr. 10, 3010 Bern, Switzerland 
a r t i c l e i n f o 
Article history: 
Received 27 September 2018 
Revised 8 October 2018 
Accepted 13 October 2018 
Keywords: 
Microwave ablation 
Computed tomography based 
navigation 
Liver 
Minimally-invasive treatment 
a b s t r a c t 
For percutaneous minimally-invasive local ablation therapies of malignant lesions within 
the liver computed tomography (CT) fluoroscopy or ultrasound (US) can be applied for the 
positioning of ablation probes. However, lesions in liver segment I and in the upper part of 
liver segment VIII are difficult to reach with CT fluoroscopy and US guidance even for expe- 
rienced interventionalists as steep and transcostal access paths may be needed. In addition, 
there is always the risk to lacerate crucial vessels near the liver hilus. We report on the use of 
a CT-based stereotactic navigation system (CAS-One, CAScination AG, Bern, Switzerland) for 
the precise positioning of the ablation probe to perform a percutaneous stereotactic image- 
guided microwave ablation of a breast cancer liver metastasis in liver segment I that was 
unreachable with conventional CT or US guidance. Based on the initial planning scan and 
image-to-patient registration a precise positioning of the probe was possible sparing vital 
structures like the directly adjacent vulnerable vessels. The ablation was performed without 
complications fully covering the metastatic lesion with the ablation zone. To this day, there 
was no recurring tumor 18 months after the intervention. 
© 2018 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
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Introduction 
The liver is a common site for metastatic disease, espe-
cially from colorectal cancer [1] . Today surgical approaches, eg,niversity of Washington. This is an open access article under the 
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Fig. 1 – FDG PET-CT (A, arrow), MRI in hepatobilliary phase (using Gadoxetate (Primovist); B, dotted circle) and contrast 
enhanced CT in venous phase (C, dotted circle) show the metastasis in the caudate lobe, directly adjunct to the left portal 
vein and the inferior vena cava. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 resection or liver transplantation are pursued, however, only a
minority fits the necessary requirements [2] . To overcome this,
various interventional treatment options have become avail-
able. For local thermal ablation, radiofrequency ablation (RFA)
and more recently microwave ablation (MWA) have been de-
veloped. Other methods for a local therapy are laser-induced
interstitial thermotherapy, cryotherapy, computed tomogra-
phy guided interstitial high-dose rate brachytherapy, or irre-
versible electroporation [3] . In our institution MWA is the most
commonly used procedure and we report the successful treat-
ment of a breast carcinoma liver metastasis in a very unfa-
vorable location in liver segment I using CT-based stereotactic
image-guided microwave ablation (SIMWA). 
Case report 
The patient presented in this report was part of a prospec-
tive clinical study with the aim to evaluate short-term clini-
cal outcome of patients undergoing percutaneous SIMWA for
liver metastases (excluding colorectal metastases). The study
was approved by the local ethical committee. In May 2016 a
52-year-old female patient with an abnormal finding in her
right breast on the screening mammogram presented at our
institution. Biopsy revealed an invasive ductal carcinoma (es-
trogen receptor 60%, progesterone receptor 5%-20%, Ki67 25%,
HER positive). The subsequent FDG PET-CT showed an active
lesion in the caudate lobe of the liver. The final tumor stage
was T2, N0, M1. Chemotherapy with Trastuzumab (Herceptin),
Pertuzumab (Perjeta), and Docetaxel (Taxotere) with a total of
5 cycles (dose reduction of Docetaxel due to major side ef-
fects), followed by systemic therapy with Trastuzumab and
Pertuzumab was admitted. The FDG PET-CT, 4 months after
starting the chemotherapy showed decreased activity of the
liver metastases ( Fig. 1 A). Surgery of the right breast (segmen-
tal resection, negative tumor margins) was followed by adju-vant high dose brachytherapy (cumulative dose 32 Gray (Gy))
1 month later. 
Due to the unfavorable location in the caudate lobe
( Fig. 1 ) with a distance of only 4 mm to the inferior cava
vein and a distance of 3 mm to the left portal vein surgery
would be invasive and extensive. The interdisciplinary tumor
board therefore recommended a CT-based SIMWA for therapy
considering the oncological circumstances of the patient. 
As the lesion was located just between the left portal vein
and the inferior vena cava, it would have been very difficult
even for an experienced interventionalist to position the ab-
lation probe precisely within the lesion while not risking to in-
jure the vessels and otherwise to ensure a full therapeutic cov-
erage of the lesion. Therefore, a navigation system (CAS-One,
CAScination AG, Bern, Switzerland) was used to perform the
procedure. This system allows to import the imaging data of
an initial contrast enhanced CT planning scan acquired while
the patient is under general anesthesia using jet ventilation
[4] . Six markers are attached to the skin of the patient be-
fore the planning scan that allow a real-time image-to-patient
registration. A 3D planning of the precise probe access path
is based on the CT data. Real-time tracking of both the pa-
tient position and of the aiming enables the interventionalist
to insert die ablation probe in just the right angle and the ex-
act planned depth to reach the center of the planned ablation
zone. 
The initial contrast enhanced CT planning scan showed
the known metastasis with a diameter of 8 mm in liver
segment I ( Fig. 2 A). The ablation probe (Accu2ioTMA, Angio-
dynamics, NY) was introduced via a transcostal approach,
penetrating a distance of 11 cm through the liver parenchyma.
A reformatted, preinterventional control scan showed the
precise probe position in the middle of the lesion. The plan-
ning algorithm within the navigation device was used to
define the expected ablation area with a sufficient safety
margin while sparing sensible vessel structures ( Fig. 2 A).
Intensity and duration of required energy were calculated
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Fig. 2 – Prior MWA 3D planning of the ablation area (A) allows the precise definition of a safety margin while sparing 
sensible vessel structures. Post interventional control (B) shows near perfect match between planned and treated tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 and microwave ablation was applied as planned with a
power of 100W for 2 minutes. Immediate postinterventional
contrast enhanced control scan ( Fig. 2 B) revealed an ablation
area of 30 ×16 mm, exactly as planned and fully covering
the initial lesion also providing an adequate safety margin.
The inferior vena cava and the left portal vein were not
affected. 
The 3- and 6-month follow-up Gadoxetate enhanced MRI
showed expected postinterventional change with diminished
intracellular uptake of the contrast agent ( Fig. 3 B) without any
trace of residual tumor also considering MR sequences of con-
trast dynamic and diffusion-weighted imaging. 
Systemic chemotherapy with Trastuzumab and Per-
tuzumab ended in April 2017 the patient is under single
therapy with Trastuzumab until today. Discussion 
Effectiveness of local ablation procedures depends on physical
properties of the applied technique and on precise positioning
of the probe within the lesion. Temperature of the target tissue
is critical, which is influenced by tissue density, thermal con-
ductivity, and loss of temperature due to tissue perfusion (so
called heat-sink-effect). Heat is transmitted via a probe which
can be placed percutanously or laparoscopically. For success-
ful ablation the temperature should be homogenously raised
to 50 °C-60 °C [5] . In RFA heat is generated by alternating cur-
rent in the RF range of 200 Mhz-3 Ghz. Only few millimeters
of tissue surrounding the tumor undergo active heating, most
of the tissue is heated by conduction [6] . 
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Fig. 3 – In the CT control scan after the ablation the lesion is fully covered leaving the adjacent left portal vein branch and a 
major liver vein unimpaired (A, asterisks). The access route via liver parenchyma is routinely treated with small energies 
during needle retraction to prevent spreading tumor cells. The coagulated access route is nicely seen in the control scan 
after the ablation (A, dotted arrows). Six-month follow-up MRA in hepatobiliary phase using Gadoxetate shows a slightly 
retracted scar in the caudate lobe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In our case, MWA is favorable because of the superior phys-
ical properties. MWA generates radiation between 900 Mhz
and 2,4 Ghz [7] and in comparison to RFA, it is not susceptible
to increasing impedance from ablated tissue and is not com-
pletely dependent on hydrated tissue [6] . In MWA more direct
energy deposition is possible resulting in more uniform heat-
ing [8] . Furthermore, due to the close proximity to the vessels
(portal vein and hepatic vein) a significant heat-sink effect was
to expect. In MWA this effect is less evident and the proxim-
ity to large vessels is a contraindication for RFA [9] . MWA also
seems to be more effective in preventing long term progres-
sion and local recurrences [10] . 
The use of the navigation system allowed to define a safe
access route and a precise positioning of the tip of the probe
as well as a predefinition of the expected areal of ablation de-
pending on the applied energy and duration of ablation time.
A contrast-enhanced control scan after the ablation proce-
dure can be fused with the preinterventional imaging allowing
a precise control of the ablation margins. Extensive surgery
could be avoided, post-treatment complication rates are ex-
pected to be low [11] . 
Percutaneous ablation techniques are a major advance in
the treatment of liver tumors and can represent an excel-
lent alternative treatment strategy in patients that are poor
surgical candidates because of comorbidity or the underlying
liver disease. Using a CT-based stereotactic navigation system
seems technically feasible and safe and might offer minimal-
invasive treatment options for conventionally unreachable tu-
mor locations adjacent to sensible intra- and extrahepatic
structures. Statements 
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Supplementary material associated with this article can be
found, in the online version, at doi: 10.1016/j.radcr.2018.10.010 .
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